Histology and Cytology Market Expected to Reach $22.2 Billion by 2032—Allied Market Research

Histology and Cytology Market Expected to Reach $22.2 Billion by 2032

According to a new report published by Allied Market Research, titled, “Histology and Cytology Market," The histology and cytology market size was valued at $7.2 billion in 2022, and is estimated to reach $22.2 billion by 2032, growing at a CAGR of 11.9% from 2023 to 2032. The cytology segment dominated the market share in 2022 and is expected to register the highest CAGR of 12.2% during the forecast period. In addition, North America was the largest shareholder in the histology and cytology market in 2022 and Asia-Pacific is expected to register the highest CAGR during the forecast period.

Histology and cytology, integral branches of pathology, involve the examination of tissues and cells, respectively, for disease diagnosis and a comprehensive understanding of their underlying mechanisms. The market for these disciplines encompasses a broad spectrum of products and services, including instruments, consumables, and software utilized in histopathology and cytopathology laboratories.

The histology and cytology market trends such as the expanding pharmaceutical industry, the increasing elderly population, and the widespread adoption of histological and cytological analysis in clinical diagnostics drive the growth of the market. The remarkable expansion of the pharmaceutical sector is attributed to various factors, including heightened healthcare requirements, the escalating prevalence of chronic diseases, and a growing emphasis on research and development which further drives the histology and cytology market growth. For instance, according to a 2023 report by the National Investment Promotion and Facilitation Agency, it was reported that the pharmaceutical industry in India was valued at $50 billion. India is a major exporter of pharmaceuticals, with over 200+ countries served by Indian pharma exports.

As pharmaceutical companies worldwide continue to expand and diversify their product portfolios, the demand for advanced histology and cytology technologies has experienced a significant surge during histology and cytology market analysis. Histology and cytology play pivotal roles in drug discovery, disease diagnosis, and personalized medicine, aligning with the evolving needs of the pharmaceutical industry. The increase in the prevalence of cancer and other complex diseases in the region has surged the demand for accurate diagnostic tools, further driving the growth of histology and cytology market. 

The histology and cytology market size is segmented on the basis of type of examination, product, test type, application, end user, and region. On the basis of type of examination, the market is bifurcated into histology and cytology. On the basis of product, the market is bifurcated into instruments and analysis software system and consumable and reagents. On the basis of test type, the market is divided into microscopy methods, flow cytometry, and molecular genetic methods. On the basis of application, the market is divided into drug discovery and designing, clinical diagnostics, and academic research. 

On the basis of end user, the histology market size is segmented into pharma and biotech companies, CDMO, diagnostic laboratories, and others. Others include hospital and academic research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major key players that operate in the histology and cytology market are Hologic, Inc, F. Hoffmann-La Roche Ltd, Abbott, Becton, Dickinson, Danaher, Merck KGaA, Thermo Fisher Scientific, Inc, Sysmex Corporation, Trivitron Healthcare, and Koninklijke Philips N.V.

On the basis of type of examination, the cytology segment was the largest revenue contributor in 2022 and is expected to remain dominant during the forecast period. This is attributed to high adoption of the cytological analysis for various cancer cells in cancer diagnosis. However, the histology market size is expected to register the 11.2% CAGR in the forecast period.

On the basis of product, the consumable and reagents segment was the largest revenue contributor to the histology and cytology market in 2022, owing to high use of consumables such as staining agents and other reagents in almost every histological and cytological examination. However, the instruments and analysis software system segment is expected to register the highest CAGR in the forecast period. This is attributed to the growing trend toward laboratory automation.

On the basis of test type, the microscopy methods segment was the major revenue contributor histology and cytology market in 2022, owing to the high adoption of the microscopic method of examination by a large number of small-scale and medium-scale laboratories owing to limited budget. However, flow cytometry is expected to register the highest CAGR in the forecast. This is attributed to the high throughput capacity of the flow cytometer and thus is used majorly by pharmaceutical and biotech companies for R&D purposes.

On the basis of application, the drug discovery and designing segment was the largest revenue contributor in the histology market in 2022, owing to the fact that histology and cytological analysis is a crucial stage in the preclinical trial of the drug candidate. Thus, all the pharmaceutical and biotech companies use histological and cytological analysis to evaluate the efficacy of their new drug candidate. However, the clinical diagnostics segment is expected to register the highest CAGR during the histology and cytology market analysis. This is attributed to a rise in prevalence of chronic diseases such as cancer and infectious diseases.

On the basis of end user, the pharma and biotech companies’ segment held largest histology and cytology market share in 2022, owing to the high adoption of the histological and cytological analysis in drug development procedures. However, the CDMO segment is expected to register the highest CAGR in the forecast. This is attributed to surge in trend toward outsourcing clinical trials and drug development procedures.

On the basis of region, North America accounted for the largest histology and cytology market share in terms of revenue in 2022, owing to an increase in technological advancements, rise in adoption of histology & cytology products, and the presence of key market players & their offering strengthens the market position. North America has one of the highest healthcare expenditures globally. The willingness to invest in advanced healthcare infrastructure, including technological advanced histology and cytology instruments, supports market growth.

However, the Asia-Pacific region is projected to exhibit the highest CAGR during the histology and cytology market forecast. This growth is attributed to the prevalence of chronic diseases, including cancer, cardiovascular diseases, and others. This prevalence creates a sustained demand for histology and cytology instruments for diagnosis and research purposes, which further drives the market growth in the region. 

Key Findings of the Study

• By type of examination, the cytology segment was the highest contributor to the histology and cytology industry in 2022.
• By product, the consumable and reagents segment was the highest contributor to the market in 2022. However, instruments and analysis software system segment is expected to register highest CAGR during the forecast period.
• By test type, the microscopy methods segment dominated the market in 2022. However, flow cytometry segment is expected to register highest CAGR during the forecast period.
• By application, the drug discovery and designing segment dominated the market in 2022. However, clinical diagnostics segment is expected to register highest CAGR during the forecast period.
• By end user, the pharma and biotech companies segment dominated the histology and cytology industry in 2022. However, CDMO segment is expected to register highest CAGR during the forecast period.
• On the basis of region, the North America accounted for the largest share in terms of revenue in 2022. However, the Asia-Pacific region is projected to exhibit the highest CAGR in the market during the forecast period.